Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer

Journal of Cardiac Failure

Volumn 18, Issue 2, 2012, Pages 113-119

  Tarantini, Luigi ^a   Cioffi, Giovanni ^b   Gori, Stefania ^c   Tuccia, Fausto ^a   Boccardi, Lidia ^d   Bovelli, Daniella ^e   Lestuzzi, Chiara ^f   Maurea, Nicola ^g   Oliva, Stefano ^h   Russo, Giulia ⁱ   Faggiano, Pompilio ^j  

^a SAN MARTINO HOSPITAL   (Italy)

^b Villa Bianca Hospital   (Italy)

^c Ospedale SM Della Misericordia   (Italy)

^d SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^e S MARIA HOSPITAL   (Italy)

^f CRO   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

ⁱ Centro Cardiovascolare ASS 1 Triestina   (Italy)

^j SPEDALI CIVILI   (Italy)

more..

Author keywords

adjuvant chemotherapy; Breast cancer; cardiotoxicity; heart failure; trastuzumab

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CREATININE; DIURETIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; PACLITAXEL; STATIN; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOTOXICITY; CLINICAL FEATURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MORBIDITY; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASES; HUMANS; ITALY; MIDDLE AGED; RECEPTOR, ERBB-2; REGISTRIES; STROKE VOLUME;

EID: 84856439776     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2011.10.015     Document Type: Article

References (37)

1. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, and D.M. Parkin GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC cancerbase no. 10 2010 International Agency for Research on Cancer Lyon, France Available at: http://globocan.iarc.fr
2. D.J. Slamon, W. Godolphin, L.A. Jones, J.A. Holt, S.G. Wong, and D.E. Keith Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712 (Pubitemid 19147683)
3. M.A. Owens, B.C. Horten, and M.M. da Silva HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 2004 63 69 (Pubitemid 38821193)
4. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, and W.L. McGuire Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182 (Pubitemid 17231334)
5. I.L. Andrulis, S.B. Bull, M.E. Blackstein, D. Sutherland, C. Mak, S. Sidlofsky Toronto Breast Cancer Study Group neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer J Clin Oncol 16 1998 1340 1349 (Pubitemid 28175749)
6. E.H. Romond, E.A. Perez, J. Bryant, V.J. Suman, C.E. Geyer Jr., and N.E. Davidson Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
7. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith Herceptin Adjuvant (HERA) Trial Study Team Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
8. H. Joensuu, P. Bono, V. Kataja, T. Alanko, R. Kokko, and R. Asola Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer trial J Clin Oncol 27 2009 5685 5692
9. I. Smith, M. Procter, R.D. Gelber, S. Guillaume, A. Feyereislova, M. Dowsett HERA Study Team 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial Lancet 369 2007 29 36 (Pubitemid 46039831)
10. T. Abair, K. Garcia, and T. Quill The 2009 San Antonio Breast Cancer Symposium, San Antonio, TX, December 9-13, 2009 Clin Breast Cancer 10 2010 19 26
11. S.M. Ewer, and M.S. Ewer Cardiotoxicity profile of trastuzumab Drug Saf 31 2008 459 467 (Pubitemid 351695459)
12. S.A. Crone, Y.Y. Zhao, L. Fan, Y. Gu, S. Minamisawa, and Y. Liu ErbB2 is essential in the prevention of dilated cardiomyopathy Nat Med 8 2002 459 465 (Pubitemid 34546747)
13. T. Pugatsch, S. Abedat, C. Lotan, and R. Beeri Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways Breast Cancer Res 8 2006 R35
14. F. Timolati, D. Ott, L. Pentassuglia, M.N. Giraud, J.C. Perriard, and T.M. Suter Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes J Mol Cell Cardiol 41 2006 845 854 (Pubitemid 44635571)
15. I.J. Dahabreh, H. Linardou, F. Siannis, G. Fountzilas, and S. Murray Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials Oncologist 13 2008 620 630 (Pubitemid 351904907)
16. G.A. Viani, S.L. Afonso, E.J. Stefano, L.I. De Fendi, and F.V. Soares Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials BMC Cancer 7 2007 153
17. M.C. Pinder, Z. Duan, J.S. Goodwin, G.N. Hortobagyi, and S.H. Giordano Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer J Clin Oncol 25 2007 3808 3815 (Pubitemid 47477254)
18. M. Guglin, G. Hartlage, C. Reynolds, R. Chen, and V. Patel Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study J Card Fail 15 2009 651 657
19. D. Wadhwa, N. Fallah-Rad, D. Grenier, M. Krahn, T. Fang, and R. Ahmadie Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study Breast Cancer Res Treat 117 2009 357 364
20. L. Livi, S. Borghesi, I. Meattini, C. Saieva, and C. De Luca Cardillo Adiuvant trastuzumab in breast cancer: experience from the University of Florence J Chemother 22 2010 115 118
21. R. Shaffer, S. Tyldesley, M. Rolles, S. Chia, and I. Mohamed Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study Radiother Oncol 90 2009 122 126
22. C. Vicente, N. Serrano, M.J. Agustín, V. Alonso, P. Palomo, and R. Huarte Cardiotoxicity associated with trastuzumab in normal clinical practice Farm Hosp 33 2009 202 207
23. H.L. McArthur, and S. Chia Cardiotoxicity of trastuzumab in clinical practice N Engl J Med 357 2007 94 95
24. C. Lamot, S. Rottey, T. de Backer, L. van Bortel, H. Robays, and S. van Belle Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium Acta Clin Belg 65 2010 300 304
25. National Cancer Institute-Cancer Therapy Evaluation Program. Available at: http://ctep.cancer.gov/protocoldevelopment/electronic-applications/docs/ ctcv20-4-30-992.pdf.
26. M. Senni, C.M. Tribouilloy, R.J. Rodeheffer, S.J. Jacobsen, J.M. Evans, and K.R. Bailey Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991 Circulation 98 1998 2282 2289 (Pubitemid 28533847)
27. J. Lindenfeld, N.M. Albert, J.P. Boehmer, S.P. Collins, J.A. Ezekowitz, and M.M. Givertz HFSA 2010 Comprehensive Heart Failure Practice Guideline. Heart Failure Society of America J Card Fail 16 2010 e1 e194
28. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2007 2375 2414 (Pubitemid 47542237)
29. D. Cardinale, A. Colombo, R. Torrisi, M.T. Sandri, M. Civelli, and M. Salvatici Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
30. J.R. Mackey, M. Clemons, M.A. Côté, D. Delgado, S. Dent, and A. Paterson Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group Curr Oncol 15 2008 24 35
31. G.W. de Keulenaer, K. Doggen, and K. Lemmens The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy Circ Res 106 2010 35 46
32. C.C. Reynolds, G. Hartlage, R. Chen, V. Patel, and M. Guglin Can heart failure medications prevent trastuzumab-induced cardiotoxicity? J Card Fail 15 2009 651 657
33. D. Cardinale, A. Colombo, G. Lamantia, N. Colombo, M. Civelli, and G. de Giacomi Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy J Am Coll Cardiol 55 2010 213 220
34. N. Kalay, E. Basar, I. Ozdogru, O. Er, Y. Cetinkaya, A. Dogan, and T. Inanc Protective effects of carvedilol against anthracycline-induced cardiomyopathy J Am Coll Cardiol 48 2006 2258 2262 (Pubitemid 44855419)
35. E.A. Perez, V.J. Suman, N.E. Davidson, G.W. Sledge, P.A. Kaufman, and C.A. Hudis Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial J Clin Oncol 26 2008 1231 1238
36. C. Héry, J. Ferlay, M. Boniol, and P. Autier Quantification of changes in breast cancer incidence and mortality since 1990 in 35 countries with caucasian-majority populations Ann Oncol 19 2008 1187 1194 (Pubitemid 351796346)
37. A. Hurria, F.L. Wong, S. Pal, C.T. Chung, S. Bhatia, and J. Mortimer Perspectives and attitudes on the use of adjuvant chemotherapy and trastuzumab in older adults with HER-2+ breast cancer: a survey of oncologists Oncologist 14 2009 883 890